Telix Pharmaceuticals (TLX AU) is raising A$600M via convertible debentures to fund key clinical development programs across the company’s therapeutic and diagnostic portfolio.
The convertible debentures, which are due to mature in 2029, will have annual yield between 2.00% and 2.75%. These will be listed on the Singapore Exchange.
Riding on strong performance during the first half, Telix has raised full-year 2024 revenue guidance by nearly 10% at mid-point to $490M–510M (A$745M–776M), representing 48–54% YoY growth.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.